Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by R.G. Ghalie
ME-401, a NOVEL, ORAL, POTENT AND SELECTIVE INHIBITOR OF PHOSPHATIDYLINOSITOL 3-Kinase P110δ (PI3Kδ) IN EARLY CLINICAL DEVELOPMENT FOR B-Cell LYMPHOID MALIGNANCIES
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Safety, Pharmacokinetics, and Pharmacodynamics of ME-401, an Oral, Potent, and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Following Single Ascending Dose Administration to Healthy Volunteers
Clinical Therapeutics
Pharmacology
Phosphoinositide 3-Kinase-Δ (PI3Kδ); Phosphoinositide 3-Kinase Catalytic Subunit Δ-Polypeptide (PI3KCD; P110δ)
Science-Business eXchange
Clinical Development of Phosphatidylinositol 3-Kinase Inhibitors for Non-Hodgkin Lymphoma
Biomarker Research
Biochemistry
Molecular Medicine
Clinical Biochemistry
Synthesis and Characterization of a Novel Prostate Cancer-Targeted Phosphatidylinositol-3-Kinase Inhibitor Prodrug
Journal of Medicinal Chemistry
Drug Discovery
Molecular Medicine
Discovery of a Selective Inhibitor of Oncogenic B-Raf Kinase With Potent Antimelanoma Activity
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
A Novel, Highly Potent and Selective Phosphodiesterase-9 Inhibitor for the Treatment of Sickle Cell Disease
Haematologica
Hematology
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent and Selective Covalent Inhibitor of Brutons Tyrosine Kinase
Novel Immunotherapies in Lymphoid Malignancies
Nature Reviews Clinical Oncology
Oncology
Final Results of a Phase 1b Study of the Safety and Efficacy of the PI3Kδ Inhibitor Acalisib (GS-9820) in Relapsed/Refractory Lymphoid Malignancies
Blood Cancer Journal
Oncology
Hematology
